8-K: ORIC Pharmaceuticals Secures $125 Million Private Placement, Reports Promising Prostate Cancer Trial Data

ORIC Pharmaceuticals announced a $125 million private placement financing and released positive preliminary Phase 1b clinical trial data for ORIC-944 in metastatic castration-resistant prostate cancer, extending its cash runway into the second half of 2027.

Summary

• ORIC Pharmaceuticals, Inc. (ORIC) entered into a securities purchase agreement for a private placement of common stock and pre-funded warrants, aiming to raise approximately $125 million in gross proceeds.
• The private placement includes 14,130,313 shares of common stock at $6.50 per share and 5,100,532 pre-funded warrants at $6.4999 per warrant, with an exercise price of $0.0001 per share for the warrants.
• The financing is expected to close on May 29, 2025, and the net proceeds will fund research and development of clinical-stage product candidates, research programs, working capital, and general corporate purposes.
• This financing, combined with existing cash, is projected to extend the company's cash runway into the second half of 2027, covering operations through the anticipated primary endpoint readout from the first ORIC-944 Phase 3 registrational trial in prostate cancer.
• Preliminary efficacy and safety data from the ongoing Phase 1b trial of ORIC-944 in combination with AR inhibitors (apalutamide and darolutamide) in 17 mCRPC patients showed a 59% PSA50 response rate (47% confirmed) and a 24% PSA90 response rate (all confirmed).
• PSA responses were observed across all ORIC-944 dose levels (400 mg, 600 mg, 800 mg) and with both combination AR inhibitors, with the majority of patients still on therapy.
• The safety profile of ORIC-944 in combination was generally well tolerated, with the vast majority of adverse events (AEs) being Grade 1 or 2 in severity; diarrhea was the most common treatment-related AE (53% of patients), with only one Grade 3 event and no Grade 4 or 5 treatment-related AEs.

Sentiment

Score: 9

Explanation: The document conveys a highly positive sentiment due to a significant capital raise that extends the company's financial runway for several years, coupled with promising preliminary clinical trial data for a key product candidate (ORIC-944) that shows strong efficacy and a favorable safety profile, explicitly comparing favorably to industry peers. This combination of strong financial backing and positive clinical progress is very encouraging.

Positives

• Successfully secured a significant $125 million private placement, demonstrating strong investor confidence.
• The financing extends the company's cash runway into the second half of 2027, providing ample capital for ongoing and planned clinical development.
• Preliminary Phase 1b data for ORIC-944 in mCRPC showed strong efficacy with a 59% PSA50 response rate and 24% PSA90 response rate, indicating substantial clinical activity.
• ORIC-944 demonstrated a favorable safety profile in combination with AR inhibitors, with most adverse events being mild to moderate (Grade 1 or 2), suggesting suitability for long-term dosing.
• The clinical data for ORIC-944 compare favorably to other PRC2 inhibitor data, positioning it as a potentially best-in-class candidate.
• The private placement was led by SR One and included participation from notable institutional investors such as Point72, Viking Global Investors, Venrock Healthcare Capital Partners, NEA, Nextech, Vivo Capital, and NEXTBio Capital, indicating strong institutional backing.

Risks

• The completion of the private placement is subject to customary closing conditions, which may not be satisfied.
• Actual events or results may differ materially from forward-looking projections due to various factors, including market conditions.
• Risks are associated with the process of discovering, developing, and commercializing drugs that are safe and effective for human therapeutics.
• ORIC's ability to develop, initiate, or complete preclinical studies and clinical trials, obtain approvals, and commercialize product candidates is uncertain.
• Clinical trial outcomes for ORIC-944, ORIC-114, or other product candidates may differ from preclinical, initial, interim, preliminary, or expected results.
• Negative impacts of health emergencies, economic instability, or international conflicts could affect ORIC's operations, including clinical trials.
• There is a risk of termination of ORIC's license and collaboration agreements or clinical trial collaboration and supply agreements.
• The company relies on third parties, including contract manufacturers and contract research organizations.
• ORIC's ability to obtain and maintain intellectual property protection for its product candidates is a risk.
• The loss of key scientific or management personnel could adversely affect the company.
• Competition in the oncology industry is a significant risk.
• General economic and market conditions can impact the company's performance.
• Holders of Pre-Funded Warrants may not exercise if beneficial ownership would exceed 9.99% (or up to 19.99% with prior notice), limiting immediate full exercise.

Future Outlook

ORIC Pharmaceuticals expects the proceeds from the private placement, combined with existing cash, to fund its current operating plan into the second half of 2027, which includes funding through the anticipated primary endpoint readout from the first ORIC-944 Phase 3 registrational trial in prostate cancer. The company plans to complete Phase 1b dose exploration in mid-2025, evaluate two candidate recommended Phase 2 doses in the second half of 2025, and initiate its first global Phase 3 registrational trial for ORIC-944 in metastatic castration-resistant prostate cancer in the first half of 2026.

Management Comments

• Pratik S. Multani, M.D., Chief Medical Officer: "These ORIC-944 combination data demonstrate substantial clinical activity with both AR inhibitors, apalutamide and darolutamide, through early measures of efficacy (PSA50 and PSA90 response rates) and a safety profile consisting almost entirely of mild to moderate GI related adverse events, making it highly suitable for potential long term dosing."
• Jacob M. Chacko, M.D., President and Chief Executive Officer: "The data generated to date continue to demonstrate the potential of ORIC-944 to be a best-in-class PRC2 inhibitor that may benefit a broad range of patients with prostate cancer. The efficacy and safety data presented today compare favorably to other PRC2 inhibitor data presented earlier this year. We look forward to subsequent updates from the dose exploration and dose optimization portion of the Phase 1b trial over the next three quarters as we move towards initiating our first global registrational trial in 1H 2026."

Industry Context

ORIC Pharmaceuticals operates in the clinical-stage oncology sector, focusing on overcoming resistance in cancer. The positive preliminary data for ORIC-944, a PRC2 inhibitor for prostate cancer, positions the company favorably within the competitive landscape of cancer therapeutics. The explicit statement that ORIC-944's data "compare favorably to other PRC2 inhibitor data presented earlier this year" suggests a potential competitive advantage in a targeted mechanism of action for prostate cancer, an area with significant unmet medical need.

Comparison to Industry Standards

• ORIC-944's preliminary efficacy and safety data in mCRPC are stated to "compare favorably to other PRC2 inhibitor data presented earlier this year," suggesting a competitive or potentially superior profile within this class of drugs.
• The observed PSA50 response rate of 59% (47% confirmed) and PSA90 response rate of 24% in heavily pre-treated mCRPC patients (median of three prior lines of therapy) indicate strong clinical activity, which could be competitive with existing or developing AR inhibitor combination therapies.
• The safety profile, characterized by a vast majority of Grade 1 or 2 adverse events and only one Grade 3 diarrhea event, is described as "compatible with long term dosing," which is a critical factor for chronic cancer treatments and could be a differentiator compared to therapies with more severe side effects.

Corporate Governance

Stakeholder Impact

• **Shareholders:** The significant capital raise reduces immediate dilution concerns and extends the cash runway, providing financial stability. The positive clinical data for ORIC-944 could increase shareholder value by de-risking a key pipeline asset. The 60-day lock-up for officers and directors may instill confidence.
• **Patients:** The promising preliminary efficacy and safety data for ORIC-944 in mCRPC offer hope for a new, potentially best-in-class treatment option for a challenging cancer, potentially improving patient outcomes.
• **Employees:** Extended cash runway provides job security and stability for employees, allowing continued focus on research and development.
• **Creditors:** Improved financial position and extended cash runway reduce financial risk, potentially making the company a more attractive borrower or partner.
• **Investment Professionals/Analysts:** Provides clear financial and clinical milestones, enabling more precise valuation and analysis of the company's prospects.

Next Steps

• The private placement financing is expected to close on May 29, 2025.
• The company will file a registration statement with the SEC within thirty (30) days following the closing of the Private Placement for purposes of registering the resale of the Shares and Warrant Shares.
• The company plans to complete the Phase 1b dose exploration portion of the ORIC-944 trial in mid-2025.
• Two candidate Recommended Phase 2 Doses (RP2Ds) for each ORIC-944 combination will be evaluated in the dose optimization portion of the trial in the second half of 2025.
• The company expects to initiate its first global Phase 3 registrational trial for ORIC-944 in mCRPC in the first half of 2026.
• A conference call and webcast will be hosted on May 28, 2025, at 4:30 p.m. ET to discuss the announcements.

Key Dates

Recommendation

Keywords

ORIC Pharmaceuticals, oncology, prostate cancer, ORIC-944, PRC2 inhibitor, private placement, financing, clinical trial, mCRPC, biopharmaceutical, cancer resistance, drug development, equity financing, pre-funded warrants